Skip to content
Lower risk Drug recall · FDA · Published October 10, 2025

Alembic Fesoterodine Tablets Recall: Diester Impurity Risk

Alembic recalls 4mg extended-release fesoterodine tablets due to diester impurity levels exceeding safety limits. This may pose health risks. Check your prescription bottle for NDC 62332-175-30 and lot number 2405006633.

🇺🇸 FDA recall #D-0156-2026DrugAlembic ›
Take action

Contact the company

Recalling firmAlembic Pharmaceuticals LimitedFormulation Division, Village Panelav, P.O. Tajpura, Near Baska, Taluka Halol · Panchmahal, India
✎ GovInfoNow plain-language explainer

Alembic is recalling 4mg extended-release fesoterodine tablets because they contain too much diester impurity. This could cause health issues if taken as directed. The recall applies to prescription bottles with specific lot numbers and expiration dates. Read more at govinfonow.com/recall/31738-alembic-fesoterodine-tablets-recall-diester-impurity-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/31738-alembic-fesoterodine-tablets-recall-diester-impurity-risk · Updated August 17, 2026 · FDA enforcement record: FDA #D-0156-2026

Cite this page

“Alembic Fesoterodine Tablets Recall: Diester Impurity Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/31738-alembic-fesoterodine-tablets-recall-diester-impurity-risk. Based on FDA recall #D-0156-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0156-2026%22&limit=1).

Alembic Pharmaceuticals Limited voluntarily recalled one lot of Fesoterodine Fumarate, Extended-release Tablets, 4 mg, due to failed impurity specifications, the FDA said on Oct. 10, 2025. The recall affects 4,884 bottles distributed nationwide.

How to tell if you have it

  • Brand: Alembic
  • Product: Fesoterodine Fumarate, Extended-release Tablets, 4 mg, 30-count bottle
  • NDC: 62332-175-30
  • Lot #: 2405006633
  • Exp Date: 03/31/2026

The hazard

The hazard is failed impurities and degradation specifications due to levels of 'Diester Impurity' exceeding the specification limit. The FDA's FAERS database contains 386 adverse-event reports naming this product, including 347 marked serious and 33 listing a death.

Context

GovInfoNow's records show Alembic Pharmaceuticals Limited has had six other recalls since June 10, 2020. Recent similar recalls include the Alembic Fesoterodine Tablets Recall on Dec. 16, 2025, and the Alembic Doxepin Capsules Recall on July 25, 2025. Other recent recalls of similar products include the Unichem Bisoprolol/Hydrochlorothiazide Tablets Recall (Jan. 21, 2026), the Zydus Mirabegron 25mg Tablets Recall (Aug. 5, 2026), and the Sun Pharmaceutical Fexofenadine 180mg Tablets Recall (June 1, 2026).

How to tell if you have this one

Check your prescription bottle for the NDC code 62332-175-30 and lot number 2405006633. The expiration date is March 31, 2026. This product is only available by prescription.

  • Brand
    Alembic
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Your Medication

    Look for the NDC code 62332-175-30 and lot number 2405006633 on the prescription bottle.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the USA.” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA published this recall 47 days after the firm started it.

1. Firm started the recall: Oct 10, 202512. FDA classified it Class III: Nov 14, 202523. Published in FDA’s Enforcement Report: Nov 26, 202532025
  1. Firm started the recall
  2. FDA classified it Class III
  3. Published in FDA’s Enforcement Report

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0156-2026 (October 10, 2025) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0156-2026 to see it in context.
  • Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA